Cargando…

Camrelizumab in patients with advanced non-squamous non-small cell lung cancer: a cost-effective analysis in China

OBJECTIVE: Camrelizumab is a selective, humanised, high-affinity IgG(4) kappa monoclonal antibody against programmed cell death 1 that shows effective antitumour activity with acceptable toxicity in multiple tumour types. The CameL trial demonstrated that camrelizumab plus chemotherapy (CC) signific...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Qian, Zheng, Hanrui, Su, Na, Li, Qiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Health Economics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9362787/ https://www.ncbi.nlm.nih.gov/pubmed/36194670 http://dx.doi.org/10.1136/bmjopen-2022-061592

Ejemplares similares

Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China
por: Xiang, Guiyuan, et al.
Publicado: (2021)

Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy
por: Khan, Iftekhar, et al.
Publicado: (2015)

Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China
por: Shao, Taihang, et al.
Publicado: (2022)

Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China
por: Liu, Qiao, et al.
Publicado: (2020)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
por: Zeng, Xiaohui, et al.
Publicado: (2019)

Introducing the non-invasive prenatal testing for detection of Down syndrome in China: a cost-effectiveness analysis
por: Shang, Wenru, et al.
Publicado: (2021)

Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer
por: Gao, Guanghui, et al.
Publicado: (2022)

Prophylaxis for Pneumocystis carinii pneumonia in non-Hodgkin’s lymphoma undergoing R-CHOP21 in China: a meta-analysis and cost-effectiveness analysis
por: Huang, Xiaojia, et al.
Publicado: (2023)

Cost-effectiveness analysis of serplulimab combined with chemotherapy in the treatment of extensive-stage small-cell lung cancer from the perspective of the healthcare system in China
por: Long, Yunchun, et al.
Publicado: (2023)

Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China
por: Chen, Ting, et al.
Publicado: (2022)

Decreasing rates of cost-related medication non-adherence by age advancement among American generational cohorts 2004–2014: a longitudinal study
por: Zhang, James, et al.
Publicado: (2022)

Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China
por: Li, Wei, et al.
Publicado: (2023)

Camrelizumab and Apatinib Combined with Radiotherapy Is Effective in Advanced Oligometastatic Non-Small-Cell Lung Cancer
por: Ye, Wei, et al.
Publicado: (2022)

Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial
por: Xin, Wenxiu, et al.
Publicado: (2020)

OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer
por: Wen, Feng, et al.
Publicado: (2018)

Costs, consequences and value for money in non-medical prescribing: a scoping review
por: Babashahi, Saeideh, et al.
Publicado: (2023)

Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer in China
por: Qiao, Liu, et al.
Publicado: (2021)

Clinical features and direct medical cost of splenic injury in China: a cross-sectional study
por: Chen, Yong, et al.
Publicado: (2022)

Cost-effectiveness analysis of arthroscopic surgery compared with non-operative management for osteoarthritis of the knee
por: Marsh, Jacquelyn D, et al.
Publicado: (2016)

Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
por: Cai, Hongfu, et al.
Publicado: (2021)

Cost-effectiveness analysis of camrelizumab in the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
por: Yang, Fan, et al.
Publicado: (2021)

Pathways and cost-effectiveness of routine lung cancer inpatient care in rural Anhui, China: a retrospective cohort study protocol
por: Shen, XingRong, et al.
Publicado: (2018)

Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis
por: Neyt, Mattias, et al.
Publicado: (2014)

Retracted: Camrelizumab and Apatinib Combined with Radiotherapy Is Effective in Advanced Oligometastatic Non-Small-Cell Lung Cancer
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Cost-effectiveness of camrelizumab plus chemotherapy vs. chemotherapy in the first-line treatment of non-squamous NSCLC: Evidence from China
por: Dai, Hongbin, et al.
Publicado: (2023)

Cost-effectiveness of stroke care in Aboriginal and non-Aboriginal patients: an observational cohort study in the Northern Territory of Australia
por: Zhao, Yuejen, et al.
Publicado: (2017)

Expansion of non-invasive prenatal screening to the screening of 10 types of chromosomal anomalies: a cost-effectiveness analysis
por: Soukkhaphone, Bounhome, et al.
Publicado: (2023)

Modelling the household cost of paediatric malaria treatment in a rural county in Kenya: do non-user fee payments matter? A partial cost of illness analysis
por: Kodhiambo, Maurice Onditi, et al.
Publicado: (2020)

Exploring the characteristics of the high-cost population from the family perspective: a cross-sectional study in Jiangsu Province, China
por: Miao, Yudong, et al.
Publicado: (2017)

Efficacy of Camrelizumab in Advanced Non-Small-Cell Lung Cancer and Prognostic Analysis of Different PET/CT Features
por: Zou, Jinhai, et al.
Publicado: (2022)

Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma
por: Xie, Qian, et al.
Publicado: (2022)

Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer
por: Liang, Xueyan, et al.
Publicado: (2023)

Randomised controlled non-inferiority trial of primary care-based facilitated access to an alcohol reduction website: cost-effectiveness analysis
por: Hunter, Rachael, et al.
Publicado: (2017)

Effectiveness and cost-effectiveness of fining non-attendance at public hospitals: a randomised controlled trial from Danish outpatient clinics
por: Blæhr, Emely Ek, et al.
Publicado: (2018)

Corrigendum: Cost-effectiveness of avelumab maintenance therapy plus best supportive care vs. best supportive care alone for advanced or metastatic urothelial carcinoma
por: Xie, Qian, et al.
Publicado: (2022)

Cost-effectiveness of mechanical thrombectomy within 6 hours of acute ischaemic stroke in China
por: Pan, Yuesong, et al.
Publicado: (2018)

Cost-effectiveness analysis of renal replacement therapy strategies in Guangzhou city, southern China
por: Yang, Fei, et al.
Publicado: (2021)

Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies
por: Shi, Wenchuan, et al.
Publicado: (2021)

Cost-utility analysis of transcranial direct current stimulation (tDCS) in non-treatment-resistant depression: the DISCO randomised controlled study protocol
por: Sauvaget, Anne, et al.
Publicado: (2020)

Hospitalisation cost analysis on hip fracture in China: a multicentre study among 73 tertiary hospitals
por: Wang, Yilin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_t13qj3iim3dmtbmba1r2j0msh0